## DUPILUMAB TREATMENT DISCONTINUATION DUE TO LIMITING ADVERSE EFFECTS: A CASE REPORT

<u>Rodríguez-Ferreras A</u>, Ordóñez-Fernández L, Maray-Mateos I, Álvarez-Asteinza C, Lázaro-López E, Zarate-Tamames B, Pieras-López A, Velasco-Roces L, Lozano-Blázquez A. Pharmacy Department. Hospital Universitario Central de Asturias. Oviedo, Spain.



## **ATC: D11 - Other dermatological preparations**

**OBJECTIVE** 

4CPS-039

Dupilumab is an Interleukin-4 receptor antagonist approved for the treatment of moderate-severe atopic dermatitis (AD) in patients not candidates or refractory to systemic therapy. Dupilumab is not commercialized in Spain so patients must access treatment through the Compassionate Use program.

To describe a case of a patient who stopped dupilumab due to adverse events (AEs).

## **MATERIAL AND METHODS**

50-year-old male patient with severe corticodependent AD for 35 years. He had received cyclosporine, methotrexate, psoralen ultraviolet-A therapy and omalizumab, as well as several cycles of corticosteroids to control outbreaks. Dermatitis manifested mainly as lichenified plaques on face and trunk. The lack of alternatives motivated dupilumab treatment authorization. Effectiveness at week 16 would be assessed, considering as the main response variable the 50% reduction in the Eczema Area and Severity Index (EASI), EASI-50. In addition, the intensity reduction of the pruritus according to the Numerical Rating Scale (NRS) as well as the variation in the


## RESULTS

The baseline EASI, NRS and DLQI values were respectively: 23, 6 and 23. Three days after first administration, patient suffered from headache, low-grade fever and intense itching. One month later lesions were clearer and smaller, but the patient developed intense conjunctivitis requiring treatment with levocabastine. <u>The EASI, NRS and DLQI values at week 16 were respectively: 7, 8.3 and 9.</u> <u>The EASI percentage reduction was 66%</u>. Three months later conjunctivitis persisted, not improving with antihistamines and topical corticosteroids. In addition, patient referred episodes of anxiety and erectile dysfunction. These AEs were reported to the Pharmacovigilance Center. All this caused <u>treatment discontinuation</u>.



- Clinical improvement was evident, also quantitatively according to the used scales.
- Post-injection EAs are common in most patients. In this case, conjunctivitis was limiting and forced treatment suspension. EAs not described in the literature previously were found and associated with dupilumab given the temporal match.

According to subsequent experience with other patients,
prophylaxis with artificial tears can be effective in the
prevention of conjunctivitis, positioning dupilumab as an effective
alternative in patients refractory to other therapies.



http://www.eahp.eu/2 4-4CPS-039